Health
US Targets Botox, Trulicity in New Drug Price Negotiations
A doctor gives a Botox injection between a patient's eyes in Redondo Beach, California.
Photographer: Patrick T. Fallon/BloombergThe US plans to slash the price it pays for Botox and diabetes drug Trulicity, the latest medicines to be targeted under legislation that’s expected to save the government more than $200 billion over a decade.
The medications and 13 others will be subject to government price negotiations over the next year as part of President Joe Biden’s signature Inflation Reduction Act, an effort to reduce drug costs for the Medicare health program for seniors. The Trump administration had until Feb. 1 to announce the next round of drugs selected for price cuts, which will take effect in 2028.